Trial Profile
A Phase 1, Open-Label, Randomized, Crossover Study To Evaluate The Pharmacokinetics Of Single Oral Doses Of Formulated And Non-Formulated CC-122 Capsules And The Effect Of Food On The Pharmacokinetics Of CC-122 In Healthy Adult Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs Avadomide (Primary)
- Indications Diffuse large B cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 10 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Feb 2014 New trial record